STRO
Sutro Biopharma Inc (STRO)
Healthcare • NASDAQ • $21.04-0.57%
- Symbol
- STRO
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $21.04
- Daily Change
- -0.57%
- Market Cap
- $339.58M
- Trailing P/E
- N/A
- Forward P/E
- -3.05
- 52W High
- $43.85
- 52W Low
- $7.15
- Analyst Target
- $47.23
- Dividend Yield
- N/A
- Beta
- 1.51
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and inf…
Company websiteResearch STRO on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.